Ascentage Pharma Group International (AAPG) Stock Score, Valuation & Financial Research
Ascentage Pharma Group International is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 23/100.
Quick answer for AAPG
Ascentage Pharma Group International currently has a Wall Street Score of 23/100. The stored market price is $16.1. Its financial score is 20/100. Its valuation score is 0/100. These figures are a research snapshot, not a buy or sell recommendation.
What Ascentage Pharma Group International does
Based in Suzhou, China, Ascentage Pharma Group International is a biotechnology firm primarily focused on clinical-stage development. The company is dedicated to discovering and advancing therapeutic solutions for a range of medical conditions, including various cancers, chronic hepatitis B virus (HBV) infections, and age-related ailments. A cornerstone of its product pipeline is HQP1351, a BCR-ABL inhibitor specifically designed to address BCR-ABL1 mutants, notably those carrying the T315I mutation. The company's portfolio also encompasses APG-2575, an orally administered, selective Bcl-2 inhibitor aimed at treating hematologic malignancies and solid tumors. Another key asset, APG-115, is an oral small molecule that intervenes in MDM2-p53 protein-protein interactions, showing potential for both solid and blood cancers. Further bolstering its oncology efforts is APG-1252, a small molecul
AAPG financial snapshot
- Wall Street Score:
- 23/100
- Current price:
- $16.1
- Market capitalization:
- $1.50B
- Revenue:
- $152.1M
- Net income:
- $-387.4M
- Free cash flow:
- $-178.6M
- Cash:
- $281.8M
- Total debt:
- $311.4M
- EPS:
- -4.43
- Financial score:
- 20/100
- Valuation score:
- 0/100
- Revenue score:
- 41/100
What stands out
- Reported year-over-year revenue growth is +0.8%.
- Free cash flow is $-178.6M, showing cash burn in the current stored period.
- The balance sheet shows $281.8M of cash versus $311.4M of total debt, so leverage deserves attention.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 20/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-08.
How to research AAPG
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.